Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Trial Details

NCT ID
NCT06484985
Phase
PHASE1
Sponsor
Axter Therapeutics (Beijing) Co., Ltd
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • AXT-1003
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087
  • Fuzhou, China|26.06139,119.30611
  • Guangzhou, China|23.11667,113.25
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • For Ia dose escalation part only:
  • R/R NHL: Locally histopathological diagnosis of relapsed/refractory non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after th…
  • Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and metastatic solid tumors,The above subjects have pro…
  • For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →